NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.

医学 伦瓦提尼 肿瘤科 新辅助治疗 肝内胆管癌 内科学 肝细胞癌 癌症 索拉非尼 乳腺癌
作者
Jianhua Rao,Tao Wang,Jing Huang,Yongquan Chi,Yuan Cheng,Long Zhang,Xuan Xiao,Feipeng Zhu,Yong Yang,Jin‐Guo Xia,Ye Fan,Xin Lin Mu,Wei Xu,Haipeng Jiang,Ling Lü,Wentao Wang,Feng Cheng,China Liver Cancer Study Group Young Investigators (CLEAP)
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl) 被引量:3
标识
DOI:10.1200/jco.2025.43.16_suppl.e16294
摘要

e16294 Background: High recurrence rate after resection negatively impacts survival outcomes of patients (Pts) with resectable intrahepatic cholangiocarcinoma (ICC). Propensity score-matched analyses suggest neoadjuvant chemotherapy improves overall survival (OS) in patients with resectable ICC exhibiting high-risk factors. This study evaluates the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with Adebrelimab and Lenvatinib in neoadjuvant treatment of resectable ICC with high-risk recurrence factors. Methods: This multi-center, single-arm, phase II trial was conducted for Pts with resectable, high-risk ICC, defined as tumor size > 5 cm, multiple tumors, presence of radiographic major vascular invasion, or lymph node involvement. Pts received 2-4 cycles of neoadjuvant therapy, consisting of HAIC-GEMOX (Oxaliplatin 85mg/m 2 and Gemcitabine 800mg/m 2 on Days 1 Q3W), Adebrelimab (1200mg on Days 3 Q3W) and Lenvatinib (8mg on Days 5-21 Q3W) , followed by curative-intent surgical resection. The primary endpoint was completion of both neoadjuvant therapy and surgical resection. Secondary endpoints included safety, R0 resection OS, objective response rate (ORR), event-free survival (EFS), complete pathological response (pCR) and major pathological response (MPR) defined as ≤50% residual viable tumor cells in resection bed. Results: As of January 15, 2024, 16 Pts (median age 60.5 and 56% male) were enrolled from 3 sites. 11 Pts completed all neoadjuvant therapy (mean 2.3 cycles), followed by surgery. 3 Pts were still undergoing neoadjuvant therapy, and 2 Pts did not undergo surgery: one due to disease progression and the other due to adverse events. According to RECIST 1.1, 14 Pts underwent imaging evaluation. The ORR and DCR were 57.1% and 92.9% respectively (CR:7.1%, PR:50.0%, SD: 35.8%, PD:7.1%). Among 11 Pts, 11(100%) Pts achieved MPR, of which 2(18.2%) Pts achieved pCR. The R0 resection rate was 90.9%. Median size of largest tumor was 7cm and 26% were lymph node positive. 5(31.2%) Pts experienced grade ≥3 treatment-related adverse events, with the most common being hypertension, thrombocytopenia, ALT elevated, GGT elevated and cough. One patient experienced Clavien-Dindo grade 3b complications of wound ulceration. There was zero treatment related mortality. EFS and OS are immature. Conclusions: Neoadjuvant treatment with HAIC (GEMOX), Adebrelimab and Lenvatinib is feasible and safe prior to resection of ICC, without negatively affecting perioperative outcomes. Continued recruitment and follow-up are still ongoing. Clinical trial information: NCT06208462 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
摇旗呐喊完成签到,获得积分10
刚刚
汉堡包的应助被LilyDong1218采纳,获得10
1秒前
pp完成签到 ,获得积分10
1秒前
JF123_完成签到 ,获得积分10
1秒前
悟格完成签到,获得积分10
2秒前
force完成签到 ,获得积分10
2秒前
徐佳达完成签到,获得积分10
2秒前
wanci的应助被全球采纳,获得10
2秒前
xueerbx完成签到,获得积分10
2秒前
ZXD1989完成签到 ,获得积分10
3秒前
叮当完成签到,获得积分10
3秒前
托塔天李完成签到,获得积分10
3秒前
upward完成签到 ,获得积分10
3秒前
彩色的哈密瓜关注了科研通微信公众号
4秒前
2222完成签到,获得积分10
4秒前
蓝月半完成签到,获得积分10
4秒前
Griffin完成签到,获得积分10
5秒前
biiii完成签到,获得积分10
6秒前
张阳阳完成签到,获得积分10
6秒前
老迟到的贝壳完成签到,获得积分10
7秒前
啦你完成签到 ,获得积分10
7秒前
123完成签到,获得积分10
8秒前
蓝星花完成签到 ,获得积分10
8秒前
传奇3的应助被好困采纳,获得10
8秒前
铁锤牛马版举报章竟的求助涉嫌违规
8秒前
思源的应助被yyy2025采纳,获得10
8秒前
包容小鸭子完成签到,获得积分10
9秒前
yi完成签到 ,获得积分10
9秒前
221完成签到,获得积分10
9秒前
Mia完成签到,获得积分10
9秒前
9秒前
小虫子完成签到,获得积分10
10秒前
坦率的盼柳完成签到 ,获得积分10
10秒前
苒柒完成签到,获得积分10
10秒前
电麻木完成签到,获得积分10
10秒前
捕蝇草水母完成签到,获得积分10
11秒前
波哥发布了新的文献求助10
11秒前
gugugaga完成签到,获得积分10
11秒前
lht666完成签到,获得积分10
11秒前
啊萌完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039